Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalMarket Capitalization

KalVista Pharmaceuticals (KALV) EBIT Margin: 2014-2020

Historic EBIT Margin for KalVista Pharmaceuticals (KALV) over the last 6 years, with Apr 2020 value amounting to -234.23%.

  • KalVista Pharmaceuticals' EBIT Margin rose 15059.00% to -234.23% in Q2 2020 from the same period last year, while for Apr 2020 it was -319.42%, marking a year-over-year decrease of 13449.00%. This contributed to the annual value of 3,249.70% for FY2025, which is 353059.00% up from last year.
  • KalVista Pharmaceuticals' EBIT Margin amounted to -234.23% in Q2 2020, which was up 70.97% from -806.85% recorded in Q1 2020.
  • Over the past 5 years, KalVista Pharmaceuticals' EBIT Margin peaked at -61.34% during Q2 2018, and registered a low of -93,257.14% during Q1 2016.
  • Over the past 3 years, KalVista Pharmaceuticals' median EBIT Margin value was -211.37% (recorded in 2020), while the average stood at -264.18%.
  • Its EBIT Margin has fluctuated over the past 5 years, first tumbled by 2,324,286bps in 2016, then soared by 549,169bps in 2018.
  • KalVista Pharmaceuticals' EBIT Margin (Quarterly) stood at -2,043.15% in 2016, then soared by 151,635bps to -526.80% in 2017, then spiked by 43,930bps to -87.50% in 2018, then plummeted by 14,946bps to -236.96% in 2019, then surged by 15,059bps to -234.23% in 2020.
  • Its last three reported values are -234.23% in Q2 2020, -806.85% for Q1 2020, and -236.96% during Q4 2019.